Trial Profile
Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary)
- Indications Neurofibromatosis 2
- Focus Therapeutic Use
- Acronyms SEL-TH-1601
- 09 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 28 Aug 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 28 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.